Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL)

Leukemia

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004

Blood

Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann DA, Arnason JE, Deol A, Feldman TA, Andreadis CB, Ghosh M, Ma S, Schuster SJ, Gergis U, Vose JM, Soumerai JD, van Besien K, Tuazon SA, Perna SK, Ou SS, Ananthakrishnan R, Rane N, Papp E, Ansari S, Thompson EG, Okal A, Peiser L, Chen Y, Sengupta S, Ray PR, Wang J, Siddiqi T

doi: 10.1182/blood.2026033565

Lymphoma

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

Lancet

Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S, ENRICH investigators

doi: 10.1016/S0140-6736(25)01432-1

Lymphoma

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

J Clin Oncol

Maurer MJ, Prochazka VK, El-Galaly TC, Flowers CR, Villa D, Bachy E, Cahn EJ, Fournier M, Larson MC, Dietrich CE, Jakobsen LH, Ghesquières H, Kridel R, Gandhi MK, Cheah CY, Hawkes EA, Seymour JF, Freeman CL, Clausen MR, Wahlin BE, Friedberg JW, Casulo C, Habermann TM, Wang Y, Nastoupil LJ, de Nully Brown P, Belada D, Janíková A, Mocikova H, Fürst T, Feugier P, Tilly H, Haioun C, Davies AJ, Cartron G, Burack R, Chihara D, Martin P, Cohen JB, Lossos IS, Kahl BS, Sehn LH, Smedby KE, Salles G, Trneny M, Link BK, Morschhauser F, Cerhan JR

doi: 10.1200/JCO-25-00892

Lymphoma

Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma

Eur J Cancer

Al-Sarayfi D, Bult JAA, de Groen RAL, de Groot FA, Vermaat JSP, Issa D, Diepstra A, Huls G, Bellido M, Plattel W, Brink M, Nijland M

doi: 10.1016/j.ejca.2025.115776

Multiple Myeloma (MM)

Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma

Blood Cancer J

Kumar S, Knopf B, Asmus E, Muchtar E, Buadi FK, Gonsalves W, Thompson M, Dingli D, Go R, Warsame R, Kourelis T, Hwa L, Fonder A, Hobbs M, Dispenzieri A, Hayman S, Leung N, Binder M, Rajkumar SV, Gertz M, Kapoor P

doi: 10.1038/s41408-026-01567-y

EHA 2026

Leukemia

LB5001: BRUIN CLL-322: Fixed-duration pirtobrutinib plus venetoclax-rituximab outperforms venetoclax plus rituximab in patients with R/R CLL

Leukemia

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

Leukemia

Castagnetti F, Breccia M, Abruzzese E, Bassan R, Binotto G, Bonifacio M, Caocci G, Capodanno I, Cavazzini F, Cimino G, Fazi P, Gozzini A, Iurlo A, Janssen JJWM, Lunghi M, Marasca R, Martino B, Messina M, Muriano F, Paoloni F, Piciocchi A, Rosti G, Russo Rossi A, Saglio G, Sica S, Soverini S, Tafuri A, Vallisa D, Westerweel PE, Pane F

doi: 10.1038/s41375-025-02796-z

Lymphoma

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial

J Clin Oncol

Ladetto M, Gutmair K, Tavarozzi R, Pawlikowski A, Schomaker M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Horowitz NA, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Heß G, van Meerten T, Wirths S, Herhaus P, Novak U, Dierlamm J, Hänel M, Hanoun C, Sonnevi K, Visco C, Castellino C, Lemoli RM, Zilioli VR, Boccomini C, Pott C, Klapper W, Schmidt C, Dreyling M, Hoster E, European MCL Network

doi: 10.1200/JCO-26-00705

Lymphoma

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group

Eur J Cancer

Ostrowska B, Domanska-Czyz K, Giza A, Taszner M, Tomaszewska A, Targonski L, Dabrowska-Iwanicka A, Poplawska L, Konecki R, Kotarska M, Szymanski M, Borawska A, Swierkowska M, Druzd-Sitek A, Paszkiewicz-Kozik E, Mroz-Zycinska E, Zimowska-Curyło D, Owczarek-Kaczmarek J, Drozd-Sokolowska J, Tajer J, Osiadacz W, Rymkiewicz G, Michalski W, Basak G, Krzanowski J, Sacha T, Zaucha JM, Walewski J, Romejko-Jarosinska J

doi: 10.1016/j.ejca.2026.116789

Related content

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma

Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma

LB5001: BRUIN CLL-322: Fixed-duration pirtobrutinib plus venetoclax-rituximab outperforms venetoclax plus rituximab in patients with R/R CLL

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group